Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT03619213Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Primary completion
- Mar 2022
- Countries
- 20
01
Overview
A Phase 3 trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by AstraZeneca. Started Aug 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03619213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619213.